TY - JOUR
T1 - Correction
T2 - Optimising AVATAR therapy for people who hear distressing voices: study protocol for the AVATAR2 multi-centre randomised controlled trial (Trials, (2021), 22, (366), 10.1186/s13063-021-05301-w)
AU - Garety, Philippa
AU - Edwards, Clementine J.
AU - Ward, Thomas
AU - Emsley, Richard
AU - Huckvale, Mark
AU - McCrone, Paul
AU - Rus-Calafell, Mar
AU - Fornells-Ambrojo, Miriam
AU - Gumley, Andrew
AU - Haddock, Gillian
AU - Bucci, Sandra
AU - McLeod, Hamish
AU - Hardy, Amy
AU - Peters, Emmanuelle
AU - Myin-Germeys, Inez
AU - Craig, Thomas
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12
Y1 - 2024/12
N2 - Following the publication of the original article [1], we were notified that the reference numbers provided in Table 1 were incorrect. Originally published Table 1: Corrected Table 1: (Table presented.) Measure Time-point* Distress, Frequency and Severity of Voices Outcome Measures Psychotic Symptom Rating Scales – Auditory Hallucinations – a dimensional measure of hallucinations29. Includes Distress dimension (primary outcome), Total score (secondary outcome), and Frequency dimension (secondary outcome)30. Hallucinations Remission Score Screening, 1, 2, 3 Other Voices Outcome Measures Beliefs about Voices Revised (BAVQ-R)32. Voices acceptance and action scale (VAAS)33. First item (power) from the Voice Power Differential Scale34. 1, 2, 3 Experience Sampling Methodology AVATAR2 ESM Questionnaire35. 1,2,3 AVATAR2 ESM Debrief Questionnaire36. 1,2,3 Other Secondary Outcome Measures Mood: Beck Depression Inventory-II37. 1, 2, 3 Anxiety: Depression Anxiety and Stress Scales (DASS-21)38. 1,2,3 Quality of Life: Warwick-Edinburgh Mental Well-being Scale39. 1, 2, 3 Delusions: Psychotic Symptoms Rating Scale (PSYRATS-DEL)29. 1, 2, 3 Service User Led Outcome Measure: Choice of Outcome in CBT for Psychosis (CHOICE) Short Form40. 1,2,3 Trauma related symptoms – International Trauma Questionnaire (ITQ)41. 1, 2 Health Economic Outcome Measures Service use and costs: costs of the intervention (based on staff time, overheads and equipment) and the costs of other key health and social care services calculated using the42. 1, 2, 3 EQ-5D-5L43 to measure QALYs 1, 2, 3 Baseline Clinical Characteristics Voice Characterisation Checklist: Assesses the complexity in characterisation of the dominant voice. Rated as more vs. less highly characterised based on presence/absence of ascribed identity (e.g. known, name), physical characteristics (e.g. age, gender, accent) and psychosocial characteristics (e.g. intentions, thoughts, relationships)-see21. Including two items from the Voice Phenomenology Interview44. 1 Fearful Attachment Style Item from Relationships Questionnaire45. 1 Patient perceived trauma-voice links - Trauma Voice Associations Questionnaire (TVAQ) 1 Trauma history - Mini-Trauma And Life Events (TALE) checklist46. 1 Clinical Assessment Interview for Negative Symptoms (CAINS)47. 1 Identification of positive symptoms – Initial items from the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) 2.148. 1 Detailed assessment of positive symptoms - Scale for the Assessment of Positive Symptoms49. 1 Covid-19 Impact Covid-19 Context Questionnaire to assess individual circumstances during pandemic and change in voice experiences. 1, 2, 3 The original article has been corrected.
AB - Following the publication of the original article [1], we were notified that the reference numbers provided in Table 1 were incorrect. Originally published Table 1: Corrected Table 1: (Table presented.) Measure Time-point* Distress, Frequency and Severity of Voices Outcome Measures Psychotic Symptom Rating Scales – Auditory Hallucinations – a dimensional measure of hallucinations29. Includes Distress dimension (primary outcome), Total score (secondary outcome), and Frequency dimension (secondary outcome)30. Hallucinations Remission Score Screening, 1, 2, 3 Other Voices Outcome Measures Beliefs about Voices Revised (BAVQ-R)32. Voices acceptance and action scale (VAAS)33. First item (power) from the Voice Power Differential Scale34. 1, 2, 3 Experience Sampling Methodology AVATAR2 ESM Questionnaire35. 1,2,3 AVATAR2 ESM Debrief Questionnaire36. 1,2,3 Other Secondary Outcome Measures Mood: Beck Depression Inventory-II37. 1, 2, 3 Anxiety: Depression Anxiety and Stress Scales (DASS-21)38. 1,2,3 Quality of Life: Warwick-Edinburgh Mental Well-being Scale39. 1, 2, 3 Delusions: Psychotic Symptoms Rating Scale (PSYRATS-DEL)29. 1, 2, 3 Service User Led Outcome Measure: Choice of Outcome in CBT for Psychosis (CHOICE) Short Form40. 1,2,3 Trauma related symptoms – International Trauma Questionnaire (ITQ)41. 1, 2 Health Economic Outcome Measures Service use and costs: costs of the intervention (based on staff time, overheads and equipment) and the costs of other key health and social care services calculated using the42. 1, 2, 3 EQ-5D-5L43 to measure QALYs 1, 2, 3 Baseline Clinical Characteristics Voice Characterisation Checklist: Assesses the complexity in characterisation of the dominant voice. Rated as more vs. less highly characterised based on presence/absence of ascribed identity (e.g. known, name), physical characteristics (e.g. age, gender, accent) and psychosocial characteristics (e.g. intentions, thoughts, relationships)-see21. Including two items from the Voice Phenomenology Interview44. 1 Fearful Attachment Style Item from Relationships Questionnaire45. 1 Patient perceived trauma-voice links - Trauma Voice Associations Questionnaire (TVAQ) 1 Trauma history - Mini-Trauma And Life Events (TALE) checklist46. 1 Clinical Assessment Interview for Negative Symptoms (CAINS)47. 1 Identification of positive symptoms – Initial items from the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) 2.148. 1 Detailed assessment of positive symptoms - Scale for the Assessment of Positive Symptoms49. 1 Covid-19 Impact Covid-19 Context Questionnaire to assess individual circumstances during pandemic and change in voice experiences. 1, 2, 3 The original article has been corrected.
UR - http://www.scopus.com/inward/record.url?scp=85217538145&partnerID=8YFLogxK
U2 - 10.1186/s13063-024-08549-0
DO - 10.1186/s13063-024-08549-0
M3 - Comment/debate
C2 - 39614278
AN - SCOPUS:85217538145
SN - 1745-6215
VL - 25
JO - Trials
JF - Trials
IS - 1
M1 - 803
ER -